Adolor Corporation announced that it is initiating a second Phase 2 study of ADL5945 in chronic non-cancer pain patients suffering from opioid-induced constipation (OIC). This second Phase 2 study of ADL5945, which will assess a single dose of 0.25mg once daily versus placebo, is intended to complete the dosing assessment of ADL5945 in anticipation of a Phase 3 program. The Company’s first Phase 2 study of this compound was initiated in October 2010 and it is evaluating two doses of ADL5945 (0.10mg and 0.25mg) each administered twice daily in patients with OIC.
ADL5945 is a mu opiate receptor antagonist undergoing clinical development for chronic OIC.
For more information call (484) 595-1500 or visit www.adolor.com.